Elo Mutual Pension Insurance Co lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 6.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,547 shares of the medical research company’s stock after purchasing an additional 2,658 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Amgen were worth $9,572,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Jacobi Capital Management LLC grew its holdings in Amgen by 10.7% during the third quarter. Jacobi Capital Management LLC now owns 12,212 shares of the medical research company’s stock worth $2,597,000 after buying an additional 1,185 shares in the last quarter. Boston Partners grew its holdings in Amgen by 57.1% during the fourth quarter. Boston Partners now owns 1,135,035 shares of the medical research company’s stock worth $255,349,000 after buying an additional 412,337 shares in the last quarter. Equitable Holdings Inc. grew its holdings in Amgen by 11.2% during the third quarter. Equitable Holdings Inc. now owns 10,959 shares of the medical research company’s stock worth $2,330,000 after buying an additional 1,102 shares in the last quarter. Avantax Advisory Services Inc. grew its holdings in Amgen by 2.1% during the fourth quarter. Avantax Advisory Services Inc. now owns 30,188 shares of the medical research company’s stock worth $6,793,000 after buying an additional 613 shares in the last quarter. Finally, Peapack Gladstone Financial Corp grew its holdings in Amgen by 1.1% during the third quarter. Peapack Gladstone Financial Corp now owns 74,558 shares of the medical research company’s stock worth $15,855,000 after buying an additional 808 shares in the last quarter. 74.53% of the stock is currently owned by institutional investors.
Several brokerages recently issued reports on AMGN. Piper Sandler upped their price target on Amgen from $255.00 to $260.00 in a report on Thursday. Barclays upped their price objective on Amgen from $233.00 to $236.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. Jefferies Financial Group upped their price objective on Amgen from $266.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, February 9th. BMO Capital Markets reduced their price objective on Amgen from $263.00 to $243.00 in a research note on Thursday. Finally, Wells Fargo & Company upped their price objective on Amgen from $210.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 9th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $237.50.
Amgen (NASDAQ:AMGN – Get Rating) last issued its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.10 by $0.15. Amgen had a return on equity of 129.38% and a net margin of 21.75%. During the same quarter in the previous year, the business posted $3.70 EPS. Equities analysts forecast that Amgen Inc. will post 17.53 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 8th. Shareholders of record on Tuesday, May 17th will be issued a $1.94 dividend. The ex-dividend date is Monday, May 16th. This represents a $7.76 annualized dividend and a dividend yield of 3.33%. Amgen’s payout ratio is currently 76.38%.
About Amgen (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.